KAZA1
MCID: KLZ004
MIFTS: 42

Kala-Azar 1 (KAZA1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Kala-Azar 1

MalaCards integrated aliases for Kala-Azar 1:

Name: Kala-Azar 1 56
Kala-Azar, Susceptibility to, 1 56 13
Leishmaniasis 58 71
Leishmaniasis, Visceral, Susceptibility to, 1 56
Leishmaniasis, Visceral 1 56
Kaza1 56

Characteristics:

Orphanet epidemiological data:

58
leishmaniasis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Worldwide); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

OMIM 56 608207
OMIM Phenotypic Series 56 PS608207
MESH via Orphanet 44 D007896
ICD10 via Orphanet 33 B55.0 B55.1 B55.2 more
UMLS via Orphanet 72 C0023281
Orphanet 58 ORPHA507
UMLS 71 C0023281

Summaries for Kala-Azar 1

MalaCards based summary : Kala-Azar 1, also known as kala-azar, susceptibility to, 1, is related to cutaneous leishmaniasis and visceral leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kala-Azar 1 is KAZA1 (Kala-Azar (Visceral Leishmaniasis), Susceptibility To). The drugs Lidocaine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and skin, and related phenotypes are splenomegaly and hepatomegaly

More information from OMIM: 608207 PS608207

Related Diseases for Kala-Azar 1

Diseases in the Kala-Azar 1 family:

Kala-Azar 2 Kala-Azar 3

Diseases related to Kala-Azar 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 588)
# Related Disease Score Top Affiliating Genes
1 cutaneous leishmaniasis 13.0
2 visceral leishmaniasis 13.0
3 mucocutaneous leishmaniasis 12.9
4 leishmaniasis, tegumentary 12.4
5 kala-azar 2 11.7
6 kala-azar 3 11.7
7 chronic rhinitis 11.5
8 leishmaniasis 11.4
9 splenomegaly 10.9
10 pancytopenia 10.8
11 chagas disease 10.8
12 hansen's disease 10.7
13 leprosy 3 10.7
14 immune deficiency disease 10.6
15 skin disease 10.6
16 acquired immunodeficiency syndrome 10.6
17 trypanosomiasis 10.6
18 human immunodeficiency virus type 1 10.5
19 cytokine deficiency 10.5
20 neutropenia 10.5
21 triiodothyronine receptor auxiliary protein 10.5
22 allergic hypersensitivity disease 10.5
23 malaria 10.5
24 thrombocytopenia 10.5
25 sleeping sickness 10.4
26 schistosoma mansoni infection, susceptibility/ 10.4
27 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
28 schistosomiasis 10.4
29 toxoplasmosis 10.4
30 diarrhea 10.4
31 hemophagocytic lymphohistiocytosis 10.4
32 bacterial infectious disease 10.4
33 lupus erythematosus 10.4
34 exanthem 10.4
35 erysipeloid 10.3
36 glomerulonephritis 10.3
37 autoimmune disease 10.3
38 47,xyy 10.3
39 systemic lupus erythematosus 10.3
40 lepromatous leprosy 10.3
41 sporotrichosis 10.3
42 filariasis 10.3
43 uveitis 10.3
44 pulmonary tuberculosis 10.3
45 acute kidney failure 10.3
46 kidney disease 10.3
47 vasculitis 10.3
48 rheumatoid arthritis 10.3
49 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.3
50 dermatitis 10.3

Graphical network of the top 20 diseases related to Kala-Azar 1:



Diseases related to Kala-Azar 1

Symptoms & Phenotypes for Kala-Azar 1

Human phenotypes related to Kala-Azar 1:

58 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 Very frequent (99-80%)
2 hepatomegaly 58 Very frequent (99-80%)
3 fatigue 58 Occasional (29-5%)
4 arthralgia 58 Frequent (79-30%)
5 anemia 58 Frequent (79-30%)
6 pancytopenia 58 Very frequent (99-80%)
7 pallor 58 Frequent (79-30%)
8 abnormal bleeding 58 Very frequent (99-80%)
9 papule 58 Very frequent (99-80%)
10 skin ulcer 58 Very frequent (99-80%)
11 weight loss 58 Frequent (79-30%)
12 elevated hepatic transaminase 58 Frequent (79-30%)
13 thrombocytopenia 58 Occasional (29-5%)
14 anorexia 58 Occasional (29-5%)
15 episodic fever 58 Very frequent (99-80%)
16 lymphadenopathy 58 Very frequent (99-80%)
17 abnormality of oral mucosa 58 Very frequent (99-80%)
18 increased antibody level in blood 58 Frequent (79-30%)
19 leukopenia 58 Occasional (29-5%)
20 rhinitis 58 Very frequent (99-80%)
21 abnormality of the oral cavity 58 Very frequent (99-80%)
22 skin plaque 58 Very frequent (99-80%)
23 hypoalbuminemia 58 Frequent (79-30%)
24 abnormal macrophage morphology 58 Very frequent (99-80%)
25 night sweats 58 Very frequent (99-80%)

Clinical features from OMIM:

608207

UMLS symptoms related to Kala-Azar 1:


fever, pruritus, exanthema

Drugs & Therapeutics for Kala-Azar 1

Drugs for Kala-Azar 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
4
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
5
deoxycholic acid Approved Phase 4 83-44-3 222528
6
meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
7 Anesthetics Phase 4
8 Anti-Bacterial Agents Phase 4
9 Anti-Infective Agents Phase 4
10 Antifungal Agents Phase 4
11 Liposomal amphotericin B Phase 4
12 Antiparasitic Agents Phase 4
13 Antiprotozoal Agents Phase 4
14 Free Radical Scavengers Phase 4
15 Antioxidants Phase 4
16 Gastrointestinal Agents Phase 4
17 Cholagogues and Choleretics Phase 4
18 Amphotericin B, deoxycholate drug combination Phase 4
19
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
20
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
21
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
22
Pentamidine Approved, Investigational Phase 2, Phase 3 100-33-4 4735
23
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
24
Aluminum sulfate Approved Phase 2, Phase 3 10043-01-3
25
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
26
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
27
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
28
Miltefosine Approved, Investigational Phase 2, Phase 3 58066-85-6 3600
29
Paromomycin Approved, Investigational Phase 2, Phase 3 1263-89-4, 7542-37-2 165580
30
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
31
Azithromycin Approved Phase 2, Phase 3 83905-01-5 447043 55185
32
Nitric Oxide Approved Phase 3 10102-43-9 145068
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
34 Tocotrienol Investigational Phase 3 6829-55-6
35 Vaccines Phase 2, Phase 3
36 Immunologic Factors Phase 2, Phase 3
37 Platelet Aggregation Inhibitors Phase 2, Phase 3
38 Radiation-Protective Agents Phase 2, Phase 3
39 Phosphodiesterase Inhibitors Phase 2, Phase 3
40 Adjuvants, Immunologic Phase 3
41 interferons Phase 3
42 Interferon Inducers Phase 3
43 Trace Elements Phase 2, Phase 3
44 Vitamins Phase 3
45 Nutrients Phase 2, Phase 3
46 Micronutrients Phase 2, Phase 3
47 Dermatologic Agents Phase 2, Phase 3
48 Tocopherols Phase 3
49 Tocotrienols Phase 3
50 Astringents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 167)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial. Completed NCT00818818 Phase 4 Meglumine antimoniate
3 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
4 Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia. Completed NCT01462500 Phase 4 Miltefosine
5 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
6 Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
7 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
8 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
9 An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India Completed NCT01661296 Phase 4 Sodium stibogluconate
10 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
11 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
12 Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
13 Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial Unknown status NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
14 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
15 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
16 Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
17 Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients Completed NCT00257530 Phase 3 Imiquimod
18 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
19 Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
20 Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055) Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
21 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
22 Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
23 A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
24 Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
25 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
26 A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
27 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
28 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
29 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
30 Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis Completed NCT00351520 Phase 3 Miltefose
31 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
32 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
33 Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
34 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
35 Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
36 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
37 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
38 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
39 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
40 Double Blind, Randomized, Placebo Controlled Clinical Trial for the Treatment of Diabetic Foot Ulcers, Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
41 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Recruiting NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
42 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
43 Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
44 Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
45 Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
46 Effectiveness, Safety and Feasibility of Thermotherapy With the Hand-held Exothermic Crystallization Thermotherapy for Cutaneous Leishmaniasis (HECT-CL), Device for Cutaneous Leishmaniasis in Quetta, Pakistan Terminated NCT03208543 Phase 3
47 Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
48 Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
49 EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
50 A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar). Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion

Search NIH Clinical Center for Kala-Azar 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Antileishmanial [EPC]
Itraconazole
Ketoconazole
miltefosine

Genetic Tests for Kala-Azar 1

Anatomical Context for Kala-Azar 1

MalaCards organs/tissues related to Kala-Azar 1:

40
Testes, T Cells, Skin, Bone, Bone Marrow, Liver, Monocytes

Publications for Kala-Azar 1

Articles related to Kala-Azar 1:

(show top 50) (show all 20831)
# Title Authors PMID Year
1
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. 61 56
23291585 2013
2
Genetic admixture in Brazilians exposed to infection with Leishmania chagasi. 61 56
19397557 2009
3
SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. 56 61
14523377 2004
4
A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar. 61 56
14557985 2003
5
Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. 61 56
12618857 2003
6
The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. 56 61
12475635 2002
7
Improving the serodiagnosis of canine Leishmania infantum infection in geographical areas of Brazil with different disease prevalence. 61
31832561 2020
8
A case of high altitude cutaneous leishmaniasis in a non-endemic region in Nepal. 61
31520692 2020
9
Real-time PCR to differentiate among Leishmania (Viannia) subgenus, Leishmania (Leishmania) infantum and Leishmania (Leishmania) amazonensis: Application on Brazilian clinical samples. 61
31606374 2020
10
DNA barcoding and fauna of phlebotomine sand flies (Diptera: Psychodidae: Phlebotominae) from Los Tuxtlas, Veracruz, Mexico. 61
31618609 2020
11
Infection of the equine population by Leishmania parasites. 61
31498914 2020
12
Spatial Epidemiologic Trends and Hotspots of Leishmaniasis, Sri Lanka, 2001-2018. 61
31855147 2020
13
Epidemiology and spatiotemporal analysis of visceral leishmaniasis in Palestine from 1990 to 2017. 61
31704227 2020
14
In Vivo Bioluminescent Monitoring of Parasites in BALB/c Mouse Models of Cutaneous Leishmaniasis Drug Discovery. 61
31721120 2020
15
A Leishmania donovani dominant-negative mutant for eIF2α kinase LdeK1 elicits host-protective immune response. 61
31610026 2020
16
Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake. 61
30850347 2019
17
Mining for natural product antileishmanials in a fungal extract library. 61
31208892 2019
18
Genomic analyses reveal moderate levels of ploidy, high heterozygosity and structural variations in a Colombian isolate of Leishmania (Leishmania) amazonensis. 61
31836281 2019
19
Appraisal of anti-protozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani. 61
31219348 2019
20
Leishmania RNA Virus 1 (LRV-1) in Leishmania (Viannia) braziliensis Isolates from Peru: A Description of Demographic and Clinical Correlates. 61
31837129 2019
21
Nitric oxide-loaded chitosan nanoparticles as an innovative antileishmanial platform. 61
31541732 2019
22
Molecular Evidence of Leishmania infantum and Leishmania guyanensis in Red Howler Monkey (Alouatta seniculus) from French Guiana. 61
31314697 2019
23
Synthesis and biological evaluation of thiazole derivatives as LbSOD inhibitors. 61
30734600 2019
24
Adverse reactions to meglumine antimoniate in Brazilian inpatients with visceral leishmaniases: A case series. 61
31793023 2019
25
Visceral leishmaniasis presenting as haemophagocytic lymphohistiocytosis. 61
31818895 2019
26
Electrospray mass-spectrometry guided target isolation of neolignans from Nectandra leucantha (Lauraceae) by high performance- and spiral-coil countercurrent chromatography. 61
31500882 2019
27
High levels of serum glycans monovalent IgG immune complexes detected by dissociative ELISA in experimental visceral leishmaniasis. 61
31576564 2019
28
Profiles of local and systemic inflammation in the outcome of treatment of human cutaneous leishmaniasis caused by L. Viannia. 61
31818959 2019
29
Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis. 61
31805052 2019
30
HRM-PCR is an accurate and sensitive technique for the diagnosis of cutaneous leishmaniasis as compared with conventional PCR. 61
31848842 2019
31
Use of miltefosine in a patient with mucosal leishmaniasis and HIV-coinfection: a challenge in long-term management. 61
31846999 2019
32
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. 61
31320296 2019
33
Discovery and Pharmacological Studies of 4-Hydroxyphenyl-Derived Phosphonium Salts Active in a Mouse Model of Visceral Leishmaniasis. 61
31702921 2019
34
Development and evaluation of novel miltefosine-polyphenol co-loaded second generation nano-transfersomes for the topical treatment of cutaneous leishmaniasis. 61
31786952 2019
35
Species diversity and molecular insights into phlebotomine sand flies in Sardinia (Italy)-an endemic region for leishmaniasis. 61
31813012 2019
36
Isolation and Molecular Typing of Leishmania infantum from Phlebotomus perfiliewi in a Re-Emerging Focus of Leishmaniasis, Northeastern Italy. 61
31816970 2019
37
Expression of a rK39 homologue from an Iranian Leishmania infantum isolate in Leishmania tarentolae for serodiagnosis of visceral leishmaniasis. 61
31852505 2019
38
Failure of an Innovative Low-Cost, Noninvasive Thermotherapy Device for Treating Cutaneous Leishmaniasis Caused by Leishmania tropica in Pakistan. 61
31595864 2019
39
Co-administration of chitin micro-particle and Leishmania antigen proposed a new immune adjuvant against experimental leishmaniasis. 61
31593609 2019
40
SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen Leishmania donovani. 61
31846769 2019
41
Leishmania aethiopica cell-to-cell spreading involves caspase-3, AkT and NF-κB but not PKC-δ activation and involves uptake of LAMP-1 positive bodies containing parasites. 61
31804757 2019
42
In-depth comparison of cell-based methodological approaches to determine drug susceptibility of visceral Leishmania isolates. 61
31790397 2019
43
In vitro effects of the asymmetric peptidomimetic 157, containing l-tartaric acid core and valine/leucine substituents, on Leishmania amazonensis promastigotes and amastigotes. 61
31398485 2019
44
How Lutzomyia longipalpis deals with the complement system present in the ingested blood: the role of soluble inhibitors and the adsorption of factor H by midgut. 61
31816296 2019
45
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. 61
31542713 2019
46
Characterization of Transplasma Membrane Electron Transport Chain in Wild and Drug-Resistant Leishmania donovani Promastigote and Amastigote. 61
30941668 2019
47
Biosynthesis of anti-leishmanial natural products in callus cultures of Artemisia scoparia. 61
30942629 2019
48
In silico pharmacophore modeling and simulation studies for searching potent antileishmanials targeted against Leishmania donovani nicotinamidase. 61
31733620 2019
49
Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB. 61
31678841 2019
50
DiseaSE: A biomedical text analytics system for disease symptom extraction and characterization. 61
31678590 2019

Variations for Kala-Azar 1

Expression for Kala-Azar 1

Search GEO for disease gene expression data for Kala-Azar 1.

Pathways for Kala-Azar 1

GO Terms for Kala-Azar 1

Sources for Kala-Azar 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....